奥妥珠单抗治疗利妥昔单抗耐药原发性膜性肾病的前瞻性队列研究
这项前瞻性单臂单中心开放标签试验纳入20例利妥昔单抗耐药的肾病综合征原发性膜性肾病患者,接受三次1000 mg奥妥珠单抗输注并随访≤12个月。12个月时16例达到复合终点(正常白蛋白血症及完全或部分缓解),无复发,治疗安全耐受。
要点
- 奥妥珠单抗在利妥昔单抗耐药的原发性膜性肾病中12个月复合缓解率达16/20。
- 24小时蛋白尿中位数从5.7 g降至1.3 g,血清白蛋白从2.9 g/dl升至3.9 g/dl。
- 治疗安全耐受,缓解后无复发,B细胞可重现但无抗PLA2R抗体或蛋白尿升高。
核心结论
- 奥妥珠单抗对利妥昔单抗耐药的原发性膜性肾病肾病综合征患者非常有效且安全,可实现持续缓解。
研究设计与样本
- 前瞻性、单臂、单中心、开放标签试验,纳入20例利妥昔单抗耐药的肾病综合征原发性膜性肾病成人患者。
- 患者接受三次1000 mg奥妥珠单抗输注,随访≤12个月;10例完成24个月随访。
主要发现
- 12个月时16例达到复合终点(正常白蛋白血症及完全或部分缓解),其中4例完全缓解。
- 24小时蛋白尿中位数从5.7(4.7-8.1)g降至1.3(0.5-2.7)g。
- 血清白蛋白从2.9±0.6 g/dl升至3.9±0.3 g/dl(P<0.0001)。
- 血脂异常、低钙血症和低丙种球蛋白血症显著改善,GFR稳定。
- 12个月时总B细胞和循环抗PLA2R抗体耗竭;缓解后无复发。
关键数值与推荐
- 复合终点:正常白蛋白血症且完全缓解(蛋白尿<0.3 g/d)或部分缓解(蛋白尿<3.5 g/d且较基线下降≥50%)。
临床怎么用
- 对于利妥昔单抗耐药的原发性膜性肾病肾病综合征患者,奥妥珠单抗可作为有效治疗选择。
- 治疗期间需监测蛋白尿、血清白蛋白、GFR、抗PLA2R抗体及B细胞水平。
局限性
- 单臂、单中心、开放标签设计,样本量小(20例),随访时间有限(≤12个月,部分24个月)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Approximately 30% of patients with primary membranous nephropathy (MN) and persistent nephrotic syndrome (NS) fail rituximab therapy through mechanisms that could be overcome by obinutuzumab. METHODS: In this prospective, single-arm, single-center, open-label trial, 20 consenting adults with MN and rituximab-resistant NS received three 1000 mg obinutuzumab infusions at the Bergamo Nephrology Unit (Italy) between March 2022 and February 2024 and were monitored for ≤ 12 months. The primary outcome was a composite end point of normo-albuminemia and complete (proteinuria < 0.3 g/d) or partial (proteinuria < 3.5 g/d with ≥ 50% reduction from baseline) NS remission at 12-month follow-up. Twenty-four-hour proteinuria and glomerular filtration rate (GFR) were evaluated at baseline and at 3, 6, 9, 12, 18, and 24 months posttreatment. RESULTS: At 12 months, 16 patients met the combined end point, 4 with complete remission. No patient relapsed after remission. Median (interquartile range) 24-h proteinuria decreased from 5.7 (4.7-8.1) to 1.3 (0.5-2.7) g/24 h. Albumin and IgG fractional clearances also decreased, whereas serum albumin increased from 2.9 ± 0.6 g/dl to 3.9 ± 0.3 g/dl (P < 0.0001 for all changes). Dyslipidemia, hypocalcemia, and hypo-gammaglobulinemia improved significantly and GFR stabilized. At 12 months, total B cells and circulating anti-phospholipase A2 receptor (PLA2R) antibodies were depleted. Similar findings were observed in the cohort of 10 patients who completed 24 months of follow-up. However, total B cells reemerged in the circulation without an increase in anti-PLA2R antibodies and proteinuria, or relapses. Treatment was safe and well-tolerated. CONCLUSION: Obinutuzumab treatment is extremely effective and safe in patients with MN and rituximab-resistant NS and can achieve persistent remission in this population.
引用
- Trillini M, Portalupi V, Gennarini A, et al. Prospective Cohort Study of Obinutuzumab in Rituximab-Resistant Primary Membranous Nephropathy. Kidney Int Rep. 2025. PMID: 41624448. doi:10.1016/j.ekir.2025.103728
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。